Sean Wharton
Sean Wharton is the director of the Wharton Medical Clinic in Burlington, recognized for his expertise in obesity and diabetes management. He recently expressed optimism about the new oral GLP-1 medication, orforglipron, stating it could make treatment more accessible to underserved populations worldwide.
Not in the pool (under ¢1).
Recent news mentions
Sean Wharton is a researcher in Toronto and the lead author of two publications in the New England Journal of Medicine regarding GLP-1 medications.
Ερχεται η νέα γενιά του Ozempic
Greece· 2025-11-28
Sean Wharton is the lead author of the study and medical director of the Wharton Medical Clinic in Canada.
Wegovy: dose tripla potencializa perda de peso e se aproxima de resultados de Mounjauro; veja dados
Liechtenstein· 2025-06-23Dr. Sean Wharton is the director of the Wharton Medical Clinic in Burlington, Ontario, who enrolled patients in Lilly’s study of orforglipron for obesity.
Eli Lilly weight-loss pill orforglipron ‘works as well as Ozempic’ in new trial
Australia· 2025-04-17
Sean Wharton, director of the Wharton Medical Clinic in Burlington, expressed hope that a pill could potentially bring GLP-1 treatment to underserved populations worldwide.
Pílula diária de GLP-1, classe do Ozempic, apresenta dados animadores de controle do peso e diabetesLiechtenstein· 2025-04-17
